ANPCF (CelLBxHealth) Selling, General, & Admin. Expense: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CelLBxHealth Selling, General, & Admin. Expense?

CelLBxHealth ANPCF Selling, General, & Admin. Expense is $0.00 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. CelLBxHealth's selling, general, & admin. expense for the six months ended in Jun. 2026 was $0.00 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.


CelLBxHealth  (OTCPK:ANPCF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


CelLBxHealth Selling, General, & Admin. Expense Related Terms


CelLBxHealth Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth Selling, General, & Admin. Expense Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.68 0.48 0.58 1.00

CelLBxHealth Semi-Annual Data
Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANPCF vs TMO, DHR, IDXX: Selling, General, & Admin. Expense Comparison

For the Diagnostics & Research subindustry, CelLBxHealth's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CelLBxHealth Selling, General, & Admin. Expense vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where CelLBxHealth's Selling, General, & Admin. Expense falls into.



CelLBxHealth Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $0.00 Mil mean?
CelLBxHealth (ANPCF) has a Selling, General, & Admin. Expense of $0.00 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on CelLBxHealth and its competitors.
Is CelLBxHealth's Selling, General, & Admin. Expense too high?
CelLBxHealth's current Selling, General, & Admin. Expense is $0.00 Mil.
How does CelLBxHealth's Selling, General, & Admin. Expense compare to TMO and DHR?
CelLBxHealth's Selling, General, & Admin. Expense of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Diagnostics & Research company?
A good Selling, General, & Admin. Expense depends on the Medical Diagnostics & Research industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on CelLBxHealth and its competitors. CelLBxHealth's current Selling, General, & Admin. Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (ANPCF) has a current Selling, General, & Admin. Expense of $0.00 Mil. The current Selling, General, & Admin. Expense is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For CelLBxHealth (ANPCF), the current Selling, General, & Admin. Expense is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges CLBX:UKDWV:Germany
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.